{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T03:11:00Z","timestamp":1740107460614,"version":"3.37.3"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2019,9,6]],"date-time":"2019-09-06T00:00:00Z","timestamp":1567728000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,9,6]],"date-time":"2019-09-06T00:00:00Z","timestamp":1567728000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2019,11]]},"DOI":"10.1007\/s00280-019-03943-x","type":"journal-article","created":{"date-parts":[[2019,9,6]],"date-time":"2019-09-06T14:03:57Z","timestamp":1567778637000},"page":"1089-1096","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Italian survey on cetuximab-based therapy of elderly patients with metastatic colorectal cancer"],"prefix":"10.1007","volume":"84","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7004-6862","authenticated-orcid":false,"given":"Gerardo","family":"Rosati","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raffaele","family":"Addeo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Aprile","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Avallone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Domenico","family":"Bilancia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvia","family":"Brugnatelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriella","family":"Buccafusca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiara","family":"Carlomagno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefano","family":"Cordio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara","family":"Delfanti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emanuela","family":"Dell\u2019Aquila","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maurizio","family":"Di Bisceglie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samantha","family":"Di Donato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Di Stasi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Domenico","family":"Germano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Giuliani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristina","family":"Granetto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tiziana Pia","family":"Latiano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvana","family":"Leo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paolo","family":"Tralongo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Elena","family":"Stroppolo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Filippo","family":"Venturini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Salvatore","family":"Bianco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,9,6]]},"reference":[{"key":"3943_CR1","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1016\/j.bulcan.2017.01.010","volume":"104","author":"P Tuppin","year":"2017","unstructured":"Tuppin P, Pestel L, Samson S, Cuerg A, Rivi\u00e8re S, Tala S, Denis P, Drouin J, Gissot C, Gastaldi-M\u00e9nager C, Fagot-Campagna A (2017) Poids humain et \u00e9conomique des cancers en France en 2014, les donn\u00e9es du Sniiram. Bull Cancer 104:524\u2013537","journal-title":"Bull Cancer"},{"key":"3943_CR2","unstructured":"World Cancer Research Fund International. Colorectal cancer statistics. \n                    https:\/\/www.wcrf.org\/int\/cancer-facts-figures\/data-specific-cancers\/colorectal-cancer-statistics\n                    \n                   (2016) Accessed 15 July 2018"},{"key":"3943_CR3","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.critrevonc.2010.05.009","volume":"79","author":"AA Aaldriks","year":"2011","unstructured":"Aaldriks AA, Maartense E, le Cessie S, Giltay EJ, Verlaan HA, van der Geest LG, Kloosterman-Boele WM, Peters-Dijkshoorn MT, Blansjaar BA, van Schaick HW, Nortier JW (2011) Predictive value of geriatric assessment for patients older than 70\u00a0years, treated with chemotherapy. Crit Rev Oncol Hematol 79:205\u2013212","journal-title":"Crit Rev Oncol Hematol"},{"key":"3943_CR4","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1111\/codi.12575","volume":"16","author":"M Egenvall","year":"2014","unstructured":"Egenvall M, Schubert Samuelsson K, Klarin I, L\u00f6kk J, Sj\u00f6vall A, Martling A, Gunnarsson U (2014) Management of colon cancer in the elderly: a population-based study. Color Dis 16:433\u2013441","journal-title":"Color Dis"},{"key":"3943_CR5","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.1016\/j.ejca.2012.02.057","volume":"48","author":"C Bokemeyer","year":"2012","unstructured":"Bokemeyer C, van Cutsem E, Rougier P, Ciardiello F, Heeger S, Schlichting M, Celik I, K\u00f6hne CH (2012) Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: pooled analysis of the CRYSTAL and OPUS randomised clinical trials. Eur J Cancer 48:1466\u20131475","journal-title":"Eur J Cancer"},{"key":"3943_CR6","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1093\/annonc\/mdu141","volume":"25","author":"JY Douillard","year":"2014","unstructured":"Douillard JY, Siena S, Cassidy J, Tabernero J, Burkes R, Barugel M, Humblet Y, Bodoky G, Cunningham D, Jassem J, Rivera F, Koc\u00e1kova I, Ruff P, B\u0142asi\u0144ska-Morawiec M, Smakal M, Canon JL, Rother M, Oliner KS, Tian Y, Xu F, Sidhu R (2014) Final results from PRIME: randomized phase III study of panitumumab with FOLFOX4 for first-line treatment of metastatic colorectal cancer. Ann Oncol 25:1346\u20131355","journal-title":"Ann Oncol"},{"issue":"Suppl 4","key":"3943_CR7","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1200\/jco.2016.34.4_suppl.647","volume":"34","author":"E Van Cutsem","year":"2016","unstructured":"Van Cutsem E, K\u00f6hne CH, Folprecht G, Guenther S, Beier F, Papamichael D (2016) Efficacy and safety of first-line cetuximab\u2009+\u2009FOLFIRI in older and younger patients (pts) with RAS wild-type (wt) metastatic colorectal cancer (mCRC) in the CRYSTAL study. J Clin Oncol 34(Suppl 4):647","journal-title":"J Clin Oncol"},{"issue":"Suppl 8","key":"3943_CR8","first-page":"94","volume":"21","author":"G Folprecht","year":"2010","unstructured":"Folprecht G, K\u00f6hne CH, Bokemeyer C, Rougier P, Schlichting M, Heeger S, van Cutsem E (2010) Cetuximab and 1st-line chemotherapy in elderly and younger patients with metastatic colorectal cancer (MCRC): a pooled analysis of the CRYSTAL and OPUS studies. Ann Oncol 21(Suppl 8):94","journal-title":"Ann Oncol"},{"key":"3943_CR9","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.jgo.2016.01.006","volume":"7","author":"G Rosati","year":"2016","unstructured":"Rosati G, Aprile G, Cardellino GG, Avallone A (2016) A review and assessment of currently available data of the EGFR antibodies in elderly patients with metastatic colorectal cancer. J Geriatr Oncol 7:134\u2013141","journal-title":"J Geriatr Oncol"},{"key":"3943_CR10","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1016\/S1470-2045(14)70330-4","volume":"15","author":"V Heinemann","year":"2014","unstructured":"Heinemann V, von Weikersthal LF, Decker T, Kiani A, Vehling-Kaiser U, Al-Batran SE, Heintges T, Lerchenm\u00fcller C, Kahl C, Seipelt G, Kullmann F, Stauch M, Scheithauer W, Hielscher J, Scholz M, M\u00fcller S, Link H, Niederle N, Rost A, H\u00f6ffkes HG, Moehler M, Lindig RU, Modest DP, Rossius L, Kirchner T, Jung A, Stintzing S (2014) FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial. Lancet Oncol 15:1065\u20131075","journal-title":"Lancet Oncol"},{"key":"3943_CR11","doi-asserted-by":"publisher","first-page":"2392","DOI":"10.1001\/jama.2017.7105","volume":"317","author":"AP Venook","year":"2017","unstructured":"Venook AP, Niedzwiecki D, Lenz HJ, Innocenti F, Fruth B, Meyerhardt JA, Schrag D, Greene C, O\u2019Neil BH, Atkins JN, Berry S, Polite BN, O\u2019Reilly EM, Goldberg RM, Hochster HS, Schilsky RL, Bertagnolli MM, El-Khoueiry AB, Watson P, Benson AB, Mulkerin DL, Mayer RJ, Blanke C (2017) Effect of first-line chemotherapy combined with cetuximab or bevacizumab on overall survival in patients with KRAS wild-type advanced or metastatic colorectal cancer: a randomized clinical trial. JAMA 317:2392\u20132401","journal-title":"JAMA"},{"key":"3943_CR12","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1093\/annonc\/mdx175","volume":"28","author":"D Arnold","year":"2017","unstructured":"Arnold D, Lueza B, Douillard JY, Peeters M, Lenz HJ, Venook A, Heinemann V, Van Cutsem E, Pignon JP, Tabernero J, Cervantes A, Ciardiello F (2017) Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials. Ann Oncol 28:1713\u20131729","journal-title":"Ann Oncol"},{"key":"3943_CR13","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.ejca.2016.10.007","volume":"70","author":"JW Holch","year":"2017","unstructured":"Holch JW, Ricard I, Stintzing S, Modest DP, Heinemann V (2017) The relevance of primary tumour location in patients with metastatic colorectal cancer: a meta-analysis of first-line clinical trials. Eur J Cancer 70:87\u201398","journal-title":"Eur J Cancer"},{"key":"3943_CR14","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1016\/S1470-2045(13)70154-2","volume":"14","author":"D Cunningham","year":"2013","unstructured":"Cunningham D, Lang I, Marcuello E, Lorusso V, Ocvirk J, Shin DB, Jonker D, Osborne S, Andre N, Waterkamp D, Saunders MP (2013) AVEX study investigators. Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial. Lancet Oncol 14:1077\u20131085","journal-title":"Lancet Oncol"},{"key":"3943_CR15","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1634\/theoncologist.2011-0406","volume":"17","author":"J Sastre","year":"2012","unstructured":"Sastre J, Gr\u00e1valos C, Rivera F, Massuti B, Valladares-Ayerbes M, Marcuello E, Manzano JL, Benavides M, Hidalgo M, D\u00edaz-Rubio E, Aranda E (2012) First-line cetuximab plus capecitabine in elderly patients with advanced colorectal cancer: clinical outcome and subgroup analysis according to KRAS status from a Spanish TTD Group Study. Oncologist 17:339\u2013345","journal-title":"Oncologist"},{"key":"3943_CR16","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1016\/j.jgo.2018.11.011","volume":"10","author":"D Kienle","year":"2019","unstructured":"Kienle D, Dietrich D, Ribi K, Wicki A, Quagliata L, Winterhalder RC, Koeberle D, Horber D, Bastian S, Kueng M, Saletti P, Helbling D, Baertschi D, Lugli A, Bernhard J, Andrieu C, Roger von Moos R, for the Swiss Group for Clinical Cancer Research (2019) Cetuximab monotherapy and cetuximab plus capecitabine as first-line treatment in older patients with RAS- and BRAF wild-type metastatic colorectal cancer: Results of the multicenter phase II trial SAKK 41\/10. J Geriatr Oncol 10:304\u2013310","journal-title":"J Geriatr Oncol"},{"key":"3943_CR17","doi-asserted-by":"publisher","first-page":"2040","DOI":"10.1056\/NEJMoa071834","volume":"357","author":"DJ Jonker","year":"2007","unstructured":"Jonker DJ, O\u2019Callaghan CJ, Karapetis CS, Zalcberg JR, Tu D, Au HJ, Berry SR, Krahn M, Price T, Simes RJ, Tebbutt NC, van Hazel G, Wierzbicki R, Langer C, Moore MJ (2007) Cetuximab for the treatment of colorectal cancer. N Engl J Med 357:2040\u20132048","journal-title":"N Engl J Med"},{"key":"3943_CR18","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/S1040-8428(00)00089-5","volume":"35","author":"L Balducci","year":"2000","unstructured":"Balducci L, Beghe C (2000) The application of the principles of geriatrics to the management of the older person with cancer. Crit Rev Oncol Hematol 35:147\u2013154","journal-title":"Crit Rev Oncol Hematol"},{"key":"3943_CR19","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.critrevonc.2005.06.003","volume":"55","author":"M Extermann","year":"2005","unstructured":"Extermann M, Aapro M, Bernabei R, Cohen HJ, Droz JP, Lichtman S, Mor V, Monfardini S, Repetto L, S\u00f8rbye L, Topinkova E, Task Force on CGA of the International Society of Geriatric Oncology (2005) Use of comprehensive geriatric assessment in older cancer patients: recommendations from the task force on CGA of the International Society of Geriatric Oncology (SIOG). Crit Rev Oncol Hematol 55:241\u2013252","journal-title":"Crit Rev Oncol Hematol"},{"key":"3943_CR20","doi-asserted-by":"publisher","first-page":"2166","DOI":"10.1093\/annonc\/mdr587","volume":"23","author":"CA Bellera","year":"2012","unstructured":"Bellera CA, Rainfray M, Mathoulin-Pelissier S, Mertens C, Delva F, Fonck M, Soubeyran PL (2012) Screening older cancer patients: first evaluation of the G-8 geriatric screening tool. Ann Oncol 23:2166\u20132172","journal-title":"Ann Oncol"},{"key":"3943_CR21","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1016\/j.jgo.2015.02.005","volume":"6","author":"A Luciani","year":"2015","unstructured":"Luciani A, Biganzoli L, Colloca G, Falci C, Castagneto B, Floriani I, Battisti N, Dottorini L, Ferrari D, Fiduccia P, Zafarana E, Del Monte F, Galli F, Monfardini S, Foa P (2015) Estimating the risk of chemotherapy toxicity in older patients with cancer: the role of the Vulnerable Elders Survey-13 (VES-13). J Geriatr Oncol 6:272\u2013279","journal-title":"J Geriatr Oncol"},{"key":"3943_CR22","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/j.critrevonc.2008.02.003","volume":"67","author":"M Bouchahda","year":"2008","unstructured":"Bouchahda M, Macarulla T, Spano JP, Bachet JB, Lledo G, Andre T, Landi B, Tabernero J, Karabou\u00e9 A, Domont J, Levi F, Rougier P (2008) Cetuximab efficacy and safety in a retrospective cohort of elderly patients with heavily pretreated metastatic colorectal cancer. Crit Rev Oncol Hematol 67:255\u2013262","journal-title":"Crit Rev Oncol Hematol"},{"key":"3943_CR23","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.jgo.2018.01.009","volume":"9","author":"G Rosati","year":"2018","unstructured":"Rosati G, Pinto C, Di Fabio F, Chiara S, Lolli IR, Ruggeri EM, Ciuffreda L, Ferrara R, Antonuzzo L, Adua D, Racca P, Bilancia D, Benincasa E, Stroppolo ME, Di Costanzo F (2018) Quality of life, compliance, safety and effectiveness in fit older metastatic colorectal patients with cancer treated in first-line with chemotherapy plus cetuximab: a restrospective analysis from the ObservEr study. J Geriatr Oncol 9:243\u2013248","journal-title":"J Geriatr Oncol"},{"key":"3943_CR24","doi-asserted-by":"publisher","first-page":"e000086","DOI":"10.1136\/esmoopen-2016-000086","volume":"1","author":"E Martinelli","year":"2017","unstructured":"Martinelli E, Cardone C, Troiani T, Normanno N, Pisconti S, Sforza V, Bordonaro AR, Rachiglio AM, Lambiase M, Latiano TP, Modoni G, Cordio S, Giuliani F, Biglietto M, Montesarchio V, Barone C, Tonini G, Cinieri S, Febbraro A, Rizzi D, De Vita F, Orditura M, Colucci G, Maiello E, Ciardiello F (2017) Clinical activity and tolerability of FOLFIRI and cetuximab in elderly patients with metastatic colorectal cancer in the CAPRI-GOIM first-line trial. ESMO Open 1:e000086","journal-title":"ESMO Open"},{"key":"3943_CR25","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/j.bulcan.2018.02.001","volume":"105","author":"MA Loriot","year":"2018","unstructured":"Loriot MA, Ciccolini J, Thomas F, Barin-Le-Guellec C, Royer B, Milano G, Picard N, Becquemont L, Verstuyft C, Narjoz C, Schmitt A, Bobin-Dubigeon C, Harle A, Paci A, Poinsignon V, Quaranta S, Evrard A, Hennart B, Broly F, Fonrose X, Lafay-Chebassier C, Wozny AS, Masskouri F, Boyer JC, Etienne-Grimaldi MC (2018) Dihydropyrimidine d\u00e9hydrogenase (DPD) deficiency screening and securing of fluoropyrimidine-based chemotherapies: update and recommendations of the French GPCO-Unicancer and RNPGx networks. Bull Cancer 105:397\u2013407","journal-title":"Bull Cancer"},{"key":"3943_CR26","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1007\/s00280-017-3344-3","volume":"80","author":"X Zhang","year":"2017","unstructured":"Zhang X, Yin JF, Zhang J, Kong SJ, Zhang HY, Chen XM (2017) UGT1A1*6 polymorphisms are correlated with irinotecan-induced neutropenia: a systematic review and meta-analysis. Cancer Chemother Pharmacol 80:135\u2013149","journal-title":"Cancer Chemother Pharmacol"},{"key":"3943_CR27","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1200\/JCO.2004.11.037","volume":"22","author":"A Grothey","year":"2004","unstructured":"Grothey A, Sargent D, Goldberg RM, Schmoll HJ (2004) Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol 22:1209\u20131214","journal-title":"J Clin Oncol"},{"key":"3943_CR28","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1200\/JCO.2008.21.7828","volume":"28","author":"ME Lacouture","year":"2010","unstructured":"Lacouture ME, Mitchell EP, Piperdi B, Pillai MV, Shearer H, Iannotti N, Xu F, Yassine M (2010) Skin toxicity evaluation protocol with panitumumab (STEPP), a phase II, open-label, randomized trial evaluating the impact of a pre-Emptive Skin treatment regimen on skin toxicities and quality of life in patients with metastatic colorectal cancer. J Clin Oncol 28:1351\u20131357","journal-title":"J Clin Oncol"},{"key":"3943_CR29","doi-asserted-by":"publisher","first-page":"3272","DOI":"10.1002\/cam4.888","volume":"5","author":"C Pinto","year":"2016","unstructured":"Pinto C, Di Fabio F, Rosati G, Lolli IR, Ruggeri EM, Ciuffreda L, Ferrari D, Lo Re G, Rosti G, Tralongo P, Ferrara R, Alabiso O, Chiara S, Ianniello GP, Frassoldati A, Bilancia D, Campanella GA, Signorelli C, Racca P, Benincasa E, Stroppolo ME, Di Costanzo F (2016) Observational study on quality of life, safety, and effectiveness of first-line cetuximab plus chemotherapy in KRAS wild-type metastatic colorectal cancer patients: the ObservEr Study. Cancer Med 5:3272\u20133281","journal-title":"Cancer Med"},{"key":"3943_CR30","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.ejca.2010.10.013","volume":"47","author":"MS Aapro","year":"2011","unstructured":"Aapro MS, Bohlius J, Cameron DA, Dal Lago L, Donnelly JP, Kearney N, Lyman GH, Pettengell R, Tjan-Heijnen VC, Walewski J, Weber DC, Zielinski C (2011) European Organisation for Research and Treatment of Cancer. 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer 47:8\u201332","journal-title":"Eur J Cancer"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-019-03943-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-019-03943-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-019-03943-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,4]],"date-time":"2020-09-04T23:09:01Z","timestamp":1599260941000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-019-03943-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,6]]},"references-count":30,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,11]]}},"alternative-id":["3943"],"URL":"https:\/\/doi.org\/10.1007\/s00280-019-03943-x","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"type":"print","value":"0344-5704"},{"type":"electronic","value":"1432-0843"}],"subject":[],"published":{"date-parts":[[2019,9,6]]},"assertion":[{"value":"14 May 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 August 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 September 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}